Answers are grounded in this paper and cite their sources.
This analysis demonstrates unique clonal trajectories enhance anti-PD-1 efficacy in melanoma patients, suggesting novel therapeutic insights.
Introduction: Immune checkpoint blockade (ICB), such as anti-CTLA-4 or anti-PD-1 (αPD-1), drives distinct patterns of T cell differentiation that ultimately influence treatment efficacy. However, it has been challenging to identify and define distinct T cell differentiation states in humans. We apply a novel algorithm Clonotrace (Nancy Zhang, UPenn) to define differentiation trajectories by monitoring single clones across differentiation states after αPD-1. We test the hypothesis that certain differentiation trajectories will have unique properties, including cell states and trafficking patterns, that will influence clinical efficacy. Methods: We performed single cell RNA and paired TCR sequencing on 132,898 CD8+ T cells from 36 stage III melanoma patients treated with neoadjuvant αPD-1, including 12 patients with matched tumor, uninvolved regional lymph node, and blood samples. We applied Clonotrace to define differentiation trajectories by grouping clonotypes that have a similar transcriptional footprint across CD8 cell states. We then defined these differentiation trajectories in terms of cell state composition, antigen specificity, tissue distribution, gene regulation, and association with clinical outcomes. Results: We identified 10 distinct clonal trajectories that differentiate from naïve/stem-like CD8 T cell states to exhausted and/or effector CD8 T cell states. These trajectories largely separated into two sets of clones based on antigen specificity and the expression of pathways associated with chronic stimulation. Further examination of the antigen-specific clones identified one particular trajectory (Traj 5), that was associated with clinical response. Traj 5 included clones with a unique chronic effector cell state that was able to traffic between lymph node and tumor. In contrast, Traj 1 was composed of terminally exhausted CD8 clones that were tumor-resident and associated with αPD-1 resistance. Conclusion: We identify a unique differentiation trajectory in patients that retains effector T cell differentiation in the setting of chronic stimulation. These chronic effectors retain the ability to traffic between lymph node and tumor and are associated with the efficacy of αPD-1. These findings indicate maintaining trafficking ability is essential for the efficacy of ICB. In contrast, terminal differentiation results in CD8 T cells becoming “locked” in the tissue and terminally exhausted. Citation Format: Mingshuang Wang, Guanning Wang, Khushboo Patel, Ajeya Nandi, Timmy Lai, Shira Rosenberg, Zhoumu Xiang, Stella Park, Tara C. Mitchell, Alexander C. Huang, . Anti-PD-1 efficacy is associated with a clonal trajectory composed of chronic effectors with lymph node homing capacity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2810.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: